



Arginine Vasopressin ELISA Kit

Item No. 583951

www.caymanchem.com

Customer Service 800.364.9897

Technical Support 888.526.5351

1180 E. Ellsworth Rd • Ann Arbor, MI • USA

TABLE OF CONTENTS

GENERAL INFORMATION	3	Materials Supplied
	4	Safety Data
	4	Precautions
	5	If You Have Problems
	5	Storage and Stability
	5	Materials Needed but Not Supplied
INTRODUCTION	6	Background
	7	About This Assay
	7	Description of AChE Competitive ELISAs
	9	Biochemistry of Acetylcholinesterase
	11	Definition of Key Terms
PRE-ASSAY PREPARATION	12	Buffer Preparation
	13	Sample Preparation
ASSAY PROTOCOL	15	Preparation of Assay-Specific Reagents
	18	Plate Set Up
	19	Performing the Assay
ANALYSIS	22	Calculations
	24	Performance Characteristics
RESOURCES	28	Troubleshooting
	29	References
	30	Plate Template
	31	Notes
	31	Warranty and Limitation of Remedy

GENERAL INFORMATION

Materials Supplied

Item Number	Item	96 wells Quantity/Size	480 wells Quantity/Size
10009343	AVP ELISA Antiserum	1 vial/100 dtn	1 vial/500 dtn
10009344	AVP AChE Tracer	1 vial/100 dtn	1 vial/500 dtn
10009342	AVP ELISA Standard	1 vial	1 vial
400060	ELISA Buffer Concentrate (10X)	2 vials/10 ml	4 vials/10 ml
400062	Wash Buffer Concentrate (400X)	1 vial/5 ml	1 vial/12.5 ml
400035	Polysorbate 20	1 vial/3 ml	1 vial/3 ml
400005/ 400007	Mouse Anti-Rabbit IgG Coated Plate	1 plate	5 plates
400012	96-Well Cover Sheet	1 cover	5 covers
4000050	Ellman's Reagent	3 vials/100 dtn	6 vials/250 dtn

If any of the items listed above are damaged or missing, please contact our Customer Service department at (800) 364-9897 or (734) 971-3335. We cannot accept any returns without prior authorization.



WARNING: THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Safety Data

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user **must** review the **complete** Safety Data Sheet, which has been sent *via* email to your institution.

Precautions

Please read these instructions carefully before beginning this assay.

The reagents in this kit have been tested and formulated to work exclusively with Cayman Chemical's AChE ELISA Kits. This kit may not perform as described if any reagent or procedure is replaced or modified.

When compared to quantification by LC/MS or GC/MS, it is not uncommon for immunoassays to report higher analyte concentrations. While LC/MS or GC/MS analyses typically measure only a single compound, antibodies used in immunoassays sometimes recognize not only the target molecule, but also structurally related molecules, including biologically relevant metabolites. In many cases, measurement of both the parent molecule and metabolites is more representative of the overall biological response than is the measurement of a short-lived parent molecule. It is the responsibility of the researcher to understand the limits of both assay systems and to interpret their data accordingly.

If You Have Problems

Technical Service Contact Information

Phone: 888-526-5351 (USA and Canada only) or 734-975-3888
Fax: 734-971-3641
Email: techserv@caymanchem.com
Hours: M-F 8:00 AM to 5:30 PM EST

In order for our staff to assist you quickly and efficiently, please be ready to supply the lot number of the kit (found on the outside of the box).

Storage and Stability

This kit will perform as specified if stored as directed at -20°C and used before the expiration date indicated on the outside of the box.

Materials Needed But Not Supplied

1. A plate reader capable of measuring absorbance between 405-420 nm.
2. Adjustable pipettes and a repeating pipettor.
3. A source of 'UltraPure' water. Water used to prepare all ELISA reagents and buffers must be deionized and free of trace organic contaminants ('UltraPure'). Use activated carbon filter cartridges or other organic scavengers. Glass distilled water (even if double distilled), HPLC-grade water, and sterile water (for injections) are not adequate for ELISA. *NOTE: UltraPure water is available for purchase from Cayman (Item No. 400000).*
4. Materials used for Sample Preparation (see page 13).

Background

Arginine vasopressin (AVP), is a nonapeptide hormone which plays a primary role in the regulation of renal water excretion and a secondary role in the regulation of cardiovascular function in mammals.¹⁻³ AVP is also known as argipressin, antidiuretic hormone (ADH), or simply as vasopressin.

AVP has a specific effect on epithelial cells of the urinary tract augmenting the resorption of water, resulting in concentration of urine and dilution of blood serum. AVP stimulates the constriction of capillaries and arterioles, elevating blood pressure.⁴ It also promotes contraction of the intestinal musculature, increases peristalsis,⁵ and exerts some contractile influence on the uterus.

AVP is formed by the neuronal cells of the hypothalamus and stored in the pituitary gland. It is secreted into the bloodstream in response to either a decrease in plasma volume or increase in plasma osmolarity. AVP is also released directly into the brain. The actions of AVP are mediated by stimulation of tissue-specific G protein-coupled receptors, which are currently classified into V1a vascular (V1aR), V1b pituitary (V1bR), and V2 renal (V2R) receptors.^{4,6-11} These receptors are expressed in different tissues, and regulate different functions.¹²

Normal levels of AVP in serum are 0.4-5.2 pg/ml.^{13,14} Decreased AVP release or decreased renal sensitivity to AVP can cause diabetes insipidus, a condition featuring increased sodium content in the blood, excess urine production, and thirst. High levels of AVP secretion (syndrome of inappropriate antidiuretic hormone, SIADH) and resultant low blood sodium levels occur in brain and lung diseases, such as meningitis, encephalitis, brain and lung cancer, head trauma, and also in perioperative stress. Plasma levels of AVP are elevated in patients with major and anxious-retarded depression,^{13,15} as well as patients with congestive heart failure.^{16,17}

About This Assay

Cayman's AVP ELISA Kit is a competitive assay that can be used for quantification of AVP in plasma and serum. The assay has a range from 23.4-3,000 pg/ml and a sensitivity (80% B/B₀) of approximately 50 pg/ml.

Description of AChE Competitive ELISAs

This assay is based on the competition between free AVP and an AVP Tracer (AVP linked to acetylcholinesterase (AChE) for a limited number of AVP-specific rabbit antiserum binding sites. The concentration of the AVP Tracer is held constant while the concentration of free AVP (standard or sample) varies. Thus, the amount of AVP Tracer that is able to bind to the rabbit antiserum will be inversely proportional to the concentration of free AVP in the well. This rabbit antiserum-AVP (either free or tracer) complex binds to the mouse monoclonal anti-rabbit IgG that has been previously attached to the well. The plate is washed to remove any unbound reagents and then Ellman's Reagent (which contains the substrate to AChE) is added to the well. The product of this enzymatic reaction has a distinct yellow color and absorbs strongly at 412 nm. The intensity of this color, determined spectrophotometrically, is proportional to the amount of AVP Tracer bound to the well, which is inversely proportional to the amount of free AVP present in the well during the incubation; or

$$\text{Absorbance} \propto [\text{Bound AVP Tracer}] \propto 1/[\text{AVP}]$$

A schematic of this process is shown in Figure 1 on page 8.




Figure 1. Schematic of the AChE ELISA

Biochemistry of Acetylcholinesterase

The electric organ of the electric eel, *E. electricus*, contains an avid AChE capable of massive catalytic turnover during the generation of its electrochemical discharges. The electric eel AChE has a clover leaf-shaped tertiary structure consisting of a triad of tetramers attached to a collagen-like structural fibril. This stable enzyme is capable of high turnover ($64,000 \text{ s}^{-1}$) for the hydrolysis of acetylthiocholine.

A molecule of the analyte covalently attached to a molecule of AChE serves as the tracer in AChE enzyme immunoassays. Quantification of the tracer is achieved by measuring its AChE activity with Ellman's Reagent. This reagent consists of acetylthiocholine and 5,5'-dithio-bis-(2-nitrobenzoic acid). Hydrolysis of acetylthiocholine by AChE produces thiocholine (see Figure 2, on page 10). The non-enzymatic reaction of thiocholine with 5,5'-dithio-bis-(2-nitrobenzoic acid) produces 5-thio-2-nitrobenzoic acid, which has a strong absorbance at 412 nm ($\epsilon = 13,600$).

AChE has several advantages over other enzymes commonly used for enzyme immunoassays. Unlike horseradish peroxidase, AChE does not self-inactivate during turnover. This property of AChE also allows redevelopment of the assay if it is accidentally splashed or spilled. In addition, the enzyme is highly stable under the assay conditions, has a wide pH range (pH 5-10), and is not inhibited by common buffer salts or preservatives. Since AChE is stable during the development step, it is unnecessary to use a 'stop' reagent, and the plate may be read whenever it is convenient.




Figure 2. Reaction catalyzed by acetylcholinesterase

Definition of Key Terms

Blank: background absorbance caused by Ellman's Reagent. The blank absorbance should be subtracted from the absorbance readings of all the other wells, including NSB wells.

Total Activity: total enzymatic activity of the AChE-linked tracer. This is analogous to the specific activity of a radioactive tracer.

NSB (Non-Specific Binding): non-immunological binding of the tracer to the well. Even in the absence of specific antibody a very small amount of tracer still binds to the well; the NSB is a measure of this low binding. Do not forget to subtract the Blank absorbance values.

B_0 (Maximum Binding): maximum amount of the tracer that the antibody can bind in the absence of free analyte.

% B/B_0 (%Bound/Maximum Bound): ratio of the absorbance of a particular sample or standard well to that of the maximum binding (B_0) well.

Standard Curve: a plot of the % B/B_0 values *versus* concentration of a series of wells containing various known amounts of analyte.

Dtn: determination, where one dtn is the amount of reagent used per well.

Cross Reactivity: numerical representation of the relative reactivity of this assay towards structurally related molecules as compared to the primary analyte of interest. Biomolecules that possess similar epitopes to the analyte can compete with the assay tracer for binding to the primary antibody. Substances that are superior to the analyte in displacing the tracer result in a cross reactivity that is greater than 100%. Substances that are inferior to the primary analyte in displacing the tracer result in a cross reactivity that is less than 100%. Cross reactivity is calculated by comparing the mid-point (50% B/B_0) value of the tested molecule to the mid-point (50% B/B_0) value of the primary analyte when each is measured in assay buffer using the following formula:

$$\% \text{ Cross Reactivity} = \left[\frac{50\% B/B_0 \text{ value for the primary analyte}}{50\% B/B_0 \text{ value for the potential cross reactant}} \right] \times 100\%$$

PRE-ASSAY PREPARATION

NOTE: Water used to prepare all ELISA reagents and buffers must be deionized and free of trace organic contaminants ('UltraPure'). Use activated carbon filter cartridges or other organic scavengers. Glass distilled water (even if double distilled), HPLC-grade water, and sterile water (for injections) are not adequate for ELISA. UltraPure water may be purchased from Cayman (Item No. 400000).

Buffer Preparation

Store all diluted buffers at 4°C; they will be stable for about two months.

1. ELISA Buffer Preparation

Dilute the contents of one vial of ELISA Buffer Concentrate (10X) (Item No. 400060) with 90 ml of UltraPure water. Be certain to rinse the vial to remove any salts that may have precipitated. *NOTE: It is normal for the concentrated buffer to contain crystalline salts after thawing. These will completely dissolve upon dilution with water.*

2. Wash Buffer Preparation

5 ml vial Wash Buffer Concentrate (400X) (96-well kit; Item No. 400062): Dilute to a total volume of 2 liters with UltraPure water and add 1 ml of Polysorbate 20 (Item No. 400035).

OR

12.5 ml vial Wash Buffer Concentrate (400X) (480-well kit; Item No. 400062): Dilute to a total volume of 5 liters with UltraPure water and add 2.5 ml of Polysorbate 20 (Item No. 400035).

Smaller volumes of Wash Buffer can be prepared by diluting the Wash Buffer Concentrate 1:400 and adding Polysorbate 20 (0.5 ml/liter of Wash Buffer).

NOTE: Polysorbate 20 is a viscous liquid and cannot be measured by a regular pipette. A positive displacement pipette or a syringe should be used to deliver small quantities accurately.

Sample Preparation

In general, samples can be assayed with no prior purification. However, many plasma components can cause interference and normal levels of AVP in human plasma are below detection limits of the kit. Therefore purification and concentration of plasma samples is necessary for accurate measurements. The protocol shown below is one such purification method. However, you may choose a different protocol based on your own requirements and expertise.

Plasma Purification

1. Aliquot an equal amount of each sample into clean test tubes (2 ml is recommended).
2. Dilute samples 1:6 with 4% acetic acid in water (i.e., dilute 2 ml of sample with 10 ml of 4% acetic acid in water).
3. Activate a 6 ml SPE Cartridge (C-18) (6 ml) (Item No. 400020) by rinsing with 5 ml methanol and then 5 ml UltraPure water. Do not allow the SPE Cartridge to dry.
4. Pass the sample slowly (approximately 1 ml/min) through the SPE Cartridge using gravity flow.
5. Wash the column with 7 ml of water. Let the cartridge air dry for 15-20 minutes or use vacuum drying for five minutes.
6. Elute the AVP using two applications of 1 ml of 4% acetic acid in ethanol (4 ml of glacial acetic acid added to 96 ml of absolute ethanol).
7. Dry the samples by vacuum centrifugation or under a gentle stream of nitrogen. It is imperative that all the solvent be removed as even trace quantities can affect the ELISA.
8. Resuspend the extract in 400 µl of ELISA Buffer, vortex, and perform the assay.

NOTE: This purification results in a five-fold concentration of your samples. This must be taken into account when calculating your results.

Preparation of Assay-Specific Reagents

AVP ELISA Standard

Reconstitute the contents of the AVP ELISA Standard (Item No. 10009342) in 1 ml of UltraPure water. The concentration of this solution (the bulk standard) will be 30 ng/ml. This solution is not stable at 4°C for more than 24 hours. It is stable, however, at -20°C for four weeks. If you plan to use the standard in multiple experiments, we recommend freezing it in small aliquots (100 µl) for use on different days to minimize freeze-thaw damage.

NOTE: If assaying culture medium samples that have not been diluted with ELISA Buffer, culture medium should be used in place of ELISA Buffer for dilution of the standard curve.

To prepare the standard for use in ELISA: Obtain eight clean test tubes and number them #1 through #8. Aliquot 900 µl ELISA Buffer to tube #1 and 500 µl ELISA Buffer to tubes #2-8. Transfer 100 µl of the bulk standard (30 ng/ml) to tube #1 and mix thoroughly. Serially dilute the standard by removing 500 µl from tube #1 and placing in tube #2; mix thoroughly. Next, remove 500 µl from tube #2 and place it into tube #3; mix thoroughly. Repeat this process for tubes #4-8. The diluted standards may be stored at 4°C for no more than 24 hours.




Figure 3. Recovery of AVP from plasma following C-18 purification




Figure 4. Preparation of the AVP standards

AVP AChE Tracer

Reconstitute the AVP AChE Tracer as follows:

100 dtn AVP AChE Tracer (96-well kit; Item No. 10009344): Reconstitute with 6 ml ELISA Buffer.

OR

500 dtn AVP AChE Tracer (480-well kit; Item No. 10009344): Reconstitute with 30 ml ELISA Buffer.

Store the reconstituted AVP AChE Tracer at 4°C (*do not freeze!*) and use within four weeks. A 20% surplus of tracer has been included to account for any incidental losses.

AVP ELISA Antiserum

Reconstitute the AVP ELISA Antiserum as follows:

100 dtn AVP ELISA Antiserum (96-well kit; Item No. 10009343): Reconstitute with 6 ml ELISA Buffer.

OR

500 dtn AVP ELISA Antiserum (480-well kit; Item No. 10009343): Reconstitute with 30 ml ELISA Buffer.

Store the reconstituted AVP ELISA Antiserum at 4°C. It will be stable for at least four weeks. A 20% surplus of antiserum has been included to account for any incidental losses.

Plate Set Up

The 96-well plate(s) included with this kit is supplied ready to use. It is not necessary to rinse the plate(s) prior to adding the reagents. *NOTE: If you do not need to use all the strips at once, place the unused strips back in the plate packet and store at 4°C. Be sure the packet is sealed with the desiccant inside.*

Each plate or set of strips must contain a minimum of two blanks (Blk), two non-specific binding wells (NSB), two maximum binding wells (B_0), and an eight point standard curve run in duplicate. *NOTE: Each assay must contain this minimum configuration in order to ensure accurate and reproducible results.* Each sample should be assayed at two dilutions and each dilution should be assayed in duplicate. For statistical purposes, we recommend assaying samples in triplicate.

A suggested plate format is shown in Figure 5, below. The user may vary the location and type of wells present as necessary for each particular experiment. The plate format provided below has been designed to allow for easy data analysis using a convenient spreadsheet offered by Cayman (see page 22, for more details). We suggest you record the contents of each well on the template sheet provided (see page 30).

	1	2	3	4	5	6	7	8	9	10	11	12
A	Blk	S1	S1	1	1	1	9	9	9	17	17	17
B	Blk	S2	S2	2	2	2	10	10	10	18	18	18
C	NSB	S3	S3	3	3	3	11	11	11	19	19	19
D	NSB	S4	S4	4	4	4	12	12	12	20	20	20
E	B_0	S5	S5	5	5	5	13	13	13	21	21	21
F	B_0	S6	S6	6	6	6	14	14	14	22	22	22
G	B_0	S7	S7	7	7	7	15	15	15	23	23	23
H	TA	S8	S8	8	8	8	16	16	16	24	24	24

Blk - Blank
TA - Total Activity
NSB - Non-Specific Binding
 B_0 - Maximum Binding
S1-S8 - Standards 1-8
1-24 - Samples

Figure 5. Sample plate format

Performing the Assay

Pipetting Hints

- Use different tips to pipette each reagent.
- Before pipetting each reagent, equilibrate the pipette tip in that reagent (i.e., slowly fill the tip and gently expel the contents, repeat several times).
- Do not expose the pipette tip to the reagent(s) already in the well.

Addition of the Reagents

1. ELISA Buffer

Add 100 μ l ELISA Buffer to NSB wells. Add 50 μ l ELISA Buffer to B_0 wells. If culture medium was used to dilute the standard curve, substitute 50 μ l of culture medium for ELISA Buffer in the NSB and B_0 wells (i.e., add 50 μ l culture medium to NSB and B_0 wells and 50 μ l ELISA Buffer to NSB wells).

2. AVP ELISA Standard

Add 50 μ l from tube #8 to both of the lowest standard wells (S8). Add 50 μ l from tube #7 to each of the next two standard wells (S7). Continue with this procedure until all the standards are aliquoted. The same pipette tip should be used to aliquot all the standards. Before pipetting each standard, be sure to equilibrate the pipette tip in that standard.

3. Samples

Add 50 μ l of sample per well. Each sample should be assayed at a minimum of two dilutions. Each dilution should be assayed in duplicate (triplicate recommended).

4. AVP AChE Tracer

Add 50 μ l to each well *except* the TA and the Blk wells.

5. AVP ELISA Antiserum

Add 50 μ l to each well *except* the TA, the NSB, and the Blk wells.

Well	ELISA Buffer	Standard/Sample	Tracer	Antiserum
Blk	-	-	-	-
TA	-	-	5 µl (at devel. step)	-
NSB	100 µl	-	50 µl	-
B ₀	50 µl	-	50 µl	50 µl
Std./Sample	-	50 µl	50 µl	50 µl

Table 1. Pipetting summary

Incubation of the Plate

Cover each plate with plastic film (Item No. 400012) and incubate for overnight at 4°C.

Development of the Plate

1. Reconstitute Ellman's Reagent immediately before use (20 ml of reagent is sufficient to develop 100 wells):

100 dtn vial Ellman's Reagent (96-well kit; Item No. 400050): Reconstitute with 20 ml of UltraPure water.

OR

250 dtn vial Ellman's Reagent (480-well kit; Item No. 400050): Reconstitute with 50 ml of UltraPure water.

NOTE: Reconstituted Ellman's Reagent is unstable and should be used the same day it is prepared; protect the Ellman's Reagent from light when not in use. Extra vials of the reagent have been provided should a plate need to be re-developed or multiple assays be run on different days.

2. Empty the wells and rinse five times with Wash Buffer.
3. Add 200 µl of Ellman's Reagent to each well
4. Add 5 µl of tracer to the TA wells.
5. Cover the plate with plastic film. Optimum development is obtained by using an orbital shaker equipped with a large, flat cover to allow the plate(s) to develop in the dark. This assay typically develops (*i.e.*, B₀ wells ≥0.3 A.U. (blank subtracted)) in 90-120 minutes.

Reading the Plate

1. Wipe the bottom of the plate with a clean tissue to remove fingerprints, dirt, etc.
2. Remove the plate cover being careful to keep Ellman's Reagent from splashing on the cover. *NOTE: Any loss of Ellman's Reagent will affect the absorbance readings. If Ellman's Reagent is present on the cover, use a pipette to transfer the Ellman's Reagent into the well. If too much Ellman's Reagent has splashed on the cover to easily redistribute back into the wells, wash the plate three times with wash buffer and repeat the development with fresh Ellman's Reagent.*
3. Read the plate at a wavelength between 405-420 nm. The absorbance may be checked periodically until the B₀ wells have reached a minimum of 0.3 A.U. (blank subtracted). The plate should be read when the absorbance of the B₀ wells in the range of 0.3-1.0 A.U. (blank subtracted). If the absorbance of the wells exceeds 1.5, wash the plate, add fresh Ellman's Reagent and let it develop again.

ANALYSIS

Many plate readers come with data reduction software that plots data automatically. Alternatively a spreadsheet program can be used. The data should be plotted as either %B/B₀ versus log concentration using a four-parameter logistic fit or as logit B/B₀ versus log concentration using a linear fit. **NOTE:** Cayman Chemical has a computer spreadsheet available for data analysis. Please contact Technical Service or visit our website (www.caymanchem.com/analysis/elisa) to obtain a free copy of this convenient data analysis tool.

Calculations

Preparation of the Data

The following procedure is recommended for preparation of the data prior to graphical analysis.

NOTE: If the plate reader has not subtracted the absorbance readings of the blank wells from the absorbance readings of the rest of the plate, be sure to do that now.

1. Average the absorbance readings from the NSB wells.
2. Average the absorbance readings from the B₀ wells.
3. Subtract the NSB average from the B₀ average. This is the corrected B₀ or corrected maximum binding.
4. Calculate the B/B₀ (Sample or Standard Bound/Maximum Bound) for the remaining wells. To do this, subtract the average NSB absorbance from the S1 absorbance and divide by the corrected B₀ (from Step 3). Repeat for S2-S8 and all sample wells. (To obtain %B/B₀ for a logistic four-parameter fit, multiply these values by 100.)

NOTE: The TA values are not used in the standard curve calculations. Rather, they are used as a diagnostic tool; the corrected B₀ divided by the actual TA (10X measured absorbance) will give the %Bound. This value should closely approximate the %Bound that can be calculated from the **Sample Data** (see page 24). Erratic absorbance values and a low (or no) %Bound could indicate the presence of organic solvents in the buffer or other technical problems (see page 28 for **Troubleshooting**).

Plot the Standard Curve

Plot %B/B₀ for standards S1-S8 versus AVP concentration using linear (y) and log (x) axes and perform a 4-parameter logistic fit.

Alternative Plot - The data can also be linearized using a logit transformation. The equation for this conversion is shown below. **NOTE:** Do not use %B/B₀ in this calculation.

$$\text{logit (B/B}_0\text{)} = \ln [\text{B/B}_0\text{/(1 - B/B}_0\text{)}]$$

Plot the data as logit (B/B₀) versus log concentrations and perform a linear regression fit.

Determine the Sample Concentration

Calculate the B/B₀ (or %B/B₀) value for each sample. Determine the concentration of each sample by identifying the %B/B₀ on the standard curve and reading the corresponding values on the x-axis. **NOTE:** Remember to account for any concentration of the sample prior to the addition to the well. Samples with %B/B₀ values greater than 80% or less than 20% should be re-assayed as they generally fall out of the linear range of the standard curve. A 20% or greater disparity between the apparent concentration of two different dilutions of the same sample indicates interference which could be eliminated by purification.

Performance Characteristics


Sample Data

The standard curve presented here is an example of the data typically produced with this kit; however, your results will not be identical to these. You **must** run a new standard curve. Do not use the data below to determine the values of your samples. Your results could differ substantially.

	Raw Data		Average	Corrected
Total Activity	2.636	2.494	2.565	
NSB	0.019	0.018	0.0185	
B_0	0.745	0.739	0.741	0.723

Dose (pg/ml)	Raw Data		Corrected		%B/ B_0	
3,000	0.123	0.126	0.105	0.108	14.464	14.879
1,500	0.167	0.161	0.149	0.143	20.554	19.723
750	0.228	0.230	0.210	0.212	28.997	29.273
375	0.309	0.312	0.291	0.294	40.208	40.623
187.5	0.405	0.403	0.387	0.385	53.495	53.218
93.8	0.503	0.514	0.485	0.496	67.059	68.581
46.9	0.594	0.600	0.576	0.582	79.654	80.484
23.4	0.677	0.667	0.659	0.649	91.142	89.758

Table 2. Typical results



Assay Range = 23.4-3,000 pg/ml
Sensitivity (defined as 80% B/ B_0) = 50 pg/ml
Mid-point (defined as 50% B/ B_0) = 175-400 pg/ml

The sensitivity and mid-point were derived from the standard curve shown above. The standard was diluted with ELISA Buffer.

Figure 6. Typical standard curve

Precision:

The intra- and inter-assay CVs have been determined at multiple points on the standard curve. These data are summarized in the graph on page 25 and in the table below.

Dose (pg/ml)	%CV* Intra-assay variation	%CV* Inter-assay variation
3,000	8.9	6.1
1,500	7.4	5.0
750	9.3	8.0
375	9.9	6.9
187.5	10.9	4.7
93.8	10.3	8.5
46.9	13.1	10.6
23.4	20.8	13.5

Table 3. Intra- and inter-assay variation

*%CV represents the variation in concentration (not absorbance) of 40 repetitions of each point on the standard curve as determined using a reference standard curve.

Cross Reactivity:

Compound	Cross Reactivity
Arg-Vasopressin	100%
Arg-Vasotocin	100%
Dynorphin A	1.6%
Met-Enkephalin	0.08%
Leu-Enkephalin	<0.01%
Lys-Vasopressin	<0.01%
Oxytocin	<0.01%
TRH free acid	<0.01%
VIP	<0.01%

Table 4. Cross Reactivity of the AVP ELISA

RESOURCES

Troubleshooting

Problem	Possible Causes	Recommended Solutions
Erratic values; dispersion of duplicates	A. Trace organic contaminants in the water source B. Poor pipetting/technique	A. Replace activated carbon filter or change source of UltraPure water
High NSB (>10% B/B ₀)	A. Poor washing B. Exposure of NSB wells to specific antibody	A. Rewash plate and redevelop
Very low B ₀	A. Trace organic contaminants in the water source B. Plate requires additional development time C. Dilution error in preparing reagents	A. Replace activated carbon filter or change source of UltraPure water B. Return plate to shaker and re-read later
Low sensitivity (shift in dose response curve)	Standard is degraded	Replace standard
Analyses of two dilutions of a biological sample do not agree (i.e., more than 20% difference)	Interfering substances are present	Purify sample prior to analysis by ELISA ¹⁸
Only Total Activity (TA) wells develop	Trace organic contaminants in the water source	Replace activated carbon filter or change source of UltraPure water

References

1. Brownstein, M.J., Russell, J.T., and Gainer, H. *Science* **207**, 373-378 (1980).
2. Robertson, G.L. and Berl, T. Chapter 17, in *The Kidney*. Brenner, B.M. and Rector, F.C., editors, 4th, 677-736 (1991).
3. St-Louis, J. and Schiffrin, E.L. *Life Sci.* **35**, 1489-1495 (1984).
4. Thionnier, M. *Regul. Pept.* **38**, 1-11 (1992).
5. Schang, J.-C., Dapoigny, M., and Devroede, G. *Can. J. Physiol. Pharmacol.* **65**, 2137-2141 (1987).
6. Kimura, T., Tanizawa, O., Mori, K., et al. *Nature* **356**, 526-529 (1992).
7. Thibonnier, M., Auzan, C., Madhun, Z., et al. *J. Biol. Chem.* **269**(5), 3304-3310 (1994).
8. Sugimoto, T., Saito, M., Mochizuki, S., et al. *J. Biol. Chem.* **269**(43), 27088-27092 (1994).
9. Birnbaumer, M., Seibold, A., Gilbert, S., et al. *Nature* **357**, 333-335 (1992).
10. Thibonnier, M., Conarty, D.M., Preston, J.A., et al. Chapter 34, in *Vasopressin and Oxytocin*. Zingg, H.H., Bichet, D.G., and Bourque, C.W., editors, 1, Plenum Press, New York, 251-276 (1998).
11. Zenteno-Savin, T., Sada-Ovalle, I., Ceballos, G., et al. *Eur. J. Pharmacol.* **410**, 15-23 (2000).
12. Holmes, C.L., Landry, D.W., and Granton, J.T. *Critical Care* **7**, 427-434 (2003).
13. van Londen, L., Goekoop, J.G., van Kempen, G.M., et al. *Neuropsychopharmacology* **17**, 284-292 (1997).
14. Robertson, G.L., Mahr, E.A., Athar, S., et al. *J. Clin. Invest.* **52**, 2340-2352 (1973).
15. de Winter, R.F.P., van Hemert, A.M., DeRijk, R.H., et al. *Neuropsychopharmacology* **23**, 140-147 (2003).
16. Creager, M.A., Faxon, D.P., Cutler, S.S., et al. *J. Am. Coll. Cardiol.* **7**, 758-765 (1986).
17. Price, J.F., Towbin, J.A., Denfield, S.W., et al. *Circulation* **109**, 2550-2553 (2004).
18. Maxey, K.M., Maddipati, K.R., and Birkmeier, J. *J. Clin. Immunoassay* **15**, 116-120 (1992).

1								
2								
3								
4								
5								
6								
7								
8								
9								
10								
11								
12								
	A	B	C	D	E	F	G	H

NOTES

Warranty and Limitation of Remedy

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

This document is copyrighted. All rights are reserved. This document may not, in whole or part, be copied, photocopied, reproduced, translated, or reduced to any electronic medium or machine-readable form without prior consent, in writing, from Cayman Chemical Company.

©12/02/2016, Cayman Chemical Company, Ann Arbor, MI, All rights reserved. Printed in U.S.A.

